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Abstract
Background: Computed tomography (CT) biomarkers claim to improve cardiovascular risk stratification. This review
focuses on significant differences in incremental measures between adequate and inadequate reporting practise.
Methods: Studies included were those that used Framingham Risk Score as a baseline and described the
incremental value of adding calcium score or CT coronary angiogram in predicting cardiovascular risk. Searches of
MEDLINE, EMBASE, Web of Science and Cochrane Central were performed with no language restriction.
Results: Thirty five studies consisting of 206,663 patients (men = 118,114, 55.1%) were included. The baseline
Framingham Risk Score included the 1998, 2002 and 2008 iterations. Selective reporting, inconsistent reference
groupings and thresholds were found. Twelve studies (34.3%) had major and 23 (65.7%) had minor alterations and
the respective Δ AUC were significantly different (p = 0.015). When the baseline model performed well, the Δ AUC
was relatively lower with the addition of a CT biomarker (Spearman coefficient = − 0.46, p < 0.0001; n = 33; 76 pairs
of data). Other factors that influenced AUC performance included exploration of data analysis, calibration, validation,
multivariable and AUC documentation (all p < 0.05). Most studies (68.7%) that reported categorical NRI (n = 16; 46
pairs of data) subjectively drew strong conclusions along with other poor reporting practices. However, no
significant difference in values of NRI was found between adequate and inadequate reporting.
Conclusions: The widespread practice of poor reporting particularly association, discrimination, reclassification,
calibration and validation undermines the claimed incremental value of CT biomarkers over the Framingham Risk
Score alone. Inadequate reporting of discrimination inflates effect estimate, however, that is not necessarily the case
for reclassification.
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Key messages
 Selective reporting of association and non-
standardisation of cut points make evidence synthesis
difficult
 There was a negative correlation between improved
discrimination and the baseline performance of
Framingham Risk Score
 No evidence was found between poor reporting
practice and the magnitude of categorical net
reclassification index
Background
Prediction models are not perfect [1] and often have
methodological weaknesses meaning few are used in
everyday practice [2]. Framingham Risk Score (FRS) [3]
is one of the exceptions because of its extensive valid-
ation [1]. It is however, not perfect with researchers
attempting to improve prediction within the intermedi-
ate category [4]. Numerous other tests have been investi-
gated hoping to improve upon this base model [5]. This
is also in keeping with the rising interest in novel
biomarkers in medicine [6], particularly in the field of
cardiovascular [7] and cancer [8] risk prediction. In
search of a surrogate biomarker that detects subclinical
disease, coronary calcium score (CACS) has been inves-
tigated for more than a decade [9] with some proposing
screening with computed tomography (CT) in the gen-
eral population [10]. Also the quality of both primary
and secondary prognostic studies is generally poor [11]
but with a few exceptions [6]. Thoracic calcium score is
considered a relative of CACS where the Agatston
method [12] is applied to the thoracic aorta [13]. CT
coronary angiogram (CTCA) has established itself in the
acute chest pain setting and is now being investigated as
a tool of reclassifying cardiac risk based on luminal sten-
osis (and other characteristics) in the CONFIRM cohort
[14]. These imaging biomarkers generate substantial
interest and may add incremental value to traditional
Framingham risk factors. Given the known methodo-
logical issues [15–17], we looked for differences between
adequate and inadequate reporting practice.
Methods
This article is reported in line with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses [18]. The
protocol for this review was registered on PROSPERO
(2015:CRD42015023795) [19]. CLP searched MEDLINE,
EMBASE, Web of Science and the Cochrane Central
Register of Controlled Trials in July 2015. The bibli-
ographies of all included studies were searched for
further potential studies. Attempts were made to
retrieve missing information in the included publica-
tions by contacting authors and grey literature was
searched [20, 21]. Only full text publications were
included. No language restrictions were applied. An
update search was carried out in June 2016.
Screening Process & Study Selection
Two reviewers (CLP, NP) conducted title and abstract,
and then full-text screening, against the inclusion criteria.
A third reviewer (CH) was involved if disagreements were
not resolved by consensus. We only included studies that
examined Agatston or CACS, thoracic aorta calcium score
(TACS) or CTCA as new predictors and used any iter-
ation of FRS as a baseline model. We included any cohort
study that reported the association of FRS with the
defined predictors and cardiac endpoints and/or cardio-
vascular comorbidities. In addition, these studies had to
report one of the following: summary statistics indicating
incremental value of the predictor of interest in addition
to the old model, such as difference in area under the re-
ceiver operating characteristics curve (Δ AUC) [22, 23],
category-based net reclassification index (NRI) [24, 25],
integrated discrimination improvement (IDI) [26], relative
IDI (rIDI) [27] or other reclassification measures. Com-
posite endpoints [28] were considered and studies using
surrogate outcomes were excluded [29].
Data extraction
Two authors (CLP, NP) independently extracted data
from the included studies, recording the first author,
journal, publication year, outcome assessed, popula-
tion evaluated and their inferences on whether the
additional predictor improves prediction beyond the
FRS. Publications were classified whenever possible as
defined by Framingham/Wilson 1998, Framingham/
Adult Treatment Panel III (ATP) 2002 and Framing-
ham/ D’Agnostino 2008 [30, 31]. Original 95% CI,
standard error, standard deviation or p-values of sum-
mary estimates of interest were extracted [32, 33]. If
the Kaplan-Meier survival curve was available, any
missing hazard ratio was estimated (by YW) [34].
Specifically, the standard of reporting effect sizes that
signalled incremental prognostic value was evaluated.
The choice of optimal cut points/thresholds was also
examined, particularly in relation to size effects that
indicate association [35]. Various methods of quantify-
ing incremental prognostic value of an additional test
have been described [36]. We focused on the reporting
characteristics of multivariable regression, calibration, dis-
crimination and reclassification [15]. For the documenta-
tion of multivariable regression, we determined its
adequacy based on the availability of information on
whether an additional predictor was significant at p < 0.05
level, or the use of tests that penalised the inclusion of an
additional predictor. For discrimination, we assessed the
documentation of the baseline AUC of FRS and the Δ
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AUC as a result of an additional predictor of interest. The
adequacy of reporting baseline AUC relied on accurate
documentation of the FRS as originally published [15]. In
brief, the calculation of FRS could be threatened by
addition, deletion or modification of the original FRS
items. Other aspects included whether coronary heart dis-
ease (CHD) was measured and the measured population
was similar to the original FRS population. For reclassifica-
tion, all publications were searched for NRI calculation or
results. The type of NRI was verified. We considered
established categories (e.g. < 10%, 10–20%, > 20%) or any
justified use of categories as appropriate to relevant data
sets. The recommendation of reporting reclassification was
taken from [37].
Critical appraisal
We rated study quality using the Quality In Prognosis
Studies (QUIPS) tool [38]. Two reviewers (CLP, NHP)
conducted the quality assessment on the major aspects
and two reviewers (JP, YHW) assessed the statistical as-
pect of the studies independently.
Data analysis
For studies where the 95% CI or standard error was not
reported, a correlation coefficient of 0.3 between FRS
and CACS/CTCA was used to allow estimation of the
95% CI for Δ AUC based on data from [39]. Numbers
were displayed as exact numbers, median or percentages.
The alteration of the risk factors used to calculate FRS
was assessed based on previously published items [15]
with modifications. The items were scored ordinally as
either yes, no or unclear. FRS model of the 1998 iter-
ation was scored against 18 items. FRS model of the
2002 and 2008 iterations were scored against 15 items (3
diabetes related items discounted). The summation of
the individual item score indicated the overall level of
alteration which was dichotomised into a binary variable:
minor and major alterations. The threshold for dichoto-
misation was based on the median number of items
altered among the included studies. The summary of
NRIs and AUCs was displayed as medians and inter-
quartile ranges. NRIs and AUCs were subsequently split
into two groups depending on the practice of reporting
being either adequate or inadequate, or as equivalent
binary groups. The aspects of reporting were based on
previously published work on AUC [15] and NRI [37]
with adaptations. The respective groups were then com-
pared using the Wilcoxon sign rank test at significance
level p < 0.05. Specifically, we were looking for any
particular practice of reporting AUC or NRI leading to
excessive claims of any additional predictor. All statis-
tical analysis was carried out using STATA version 14.0
(StataCorp, College Station, Texas).
Results
Included studies
Eight hundred and one unique hits were screened, leading
to 35 studies (Fig. 1) encompassing 206,663 patients (men
= 118,114, 55.1%) [4, 5, 9, 13, 14, 39–68]. All publications
concluded that at least 1 imaging biomarker indicated
either independent association with composite endpoints,
improved discrimination or classification beyond trad-
itional risk factors. However, there were reservations
about TACS [13, 48] and some argued against the reclassi-
fication properties of CACS and CTCA [52, 59].
Quality of included studies
The included studies were usually at predominantly low
risk of bias with regard to study participation, measure-
ment of prognostic factors, outcome measure and con-
founding factors. There was low to moderate risk of bias
for statistical analysis because several studies selectively
reported results and/ were not clear about the process of
model building. The majority of studies were at high risk
of attrition bias because there were notable amount of
missing data and/ the number of participants’ loss to
follow-up was not accounted for. Figure 2 shows the
overall bias assessment.
The types and calculation of Framingham risk score
Eleven studies (31.4%) adopted FRS 1998 [5, 39, 44, 46,
48, 52, 53, 59, 62, 66, 67], 13 studies (37.1%) adopted
FRS 2002 [13, 40–43, 47, 49, 50, 54, 58, 63, 65, 68] and 3
studies adopted FRS 2008 [51, 56, 60]. Three studies
used both FRS 1998 and 2002 [4, 9, 14]. Two studies did
not specify the iteration of FRS used [55, 57]. According
to previously published criteria [15], additions, deletions
and modifications of risk factors are shown in Table 1.
Six studies (17.1%) did not provide any mean estimate
or a breakdown of different categories of FRS [41, 51,
55, 58, 67, 69]. The median number of items altered was
3. Using that as the threshold, twelve studies (34.3%)
had major alterations [4, 9, 39, 41–44, 46, 51, 59, 67, 68]
and 23 studies (65.7%) had minor alterations [5, 13, 14,
40, 45, 47–50, 52–58, 60–66]. Five of 23 studies that had
minor alterations did not have any components of FRS
altered [49, 55, 56, 60, 66]. Of those 5 studies, two stud-
ies did not provide any information about the compo-
nents of FRS [56, 60] and were given the benefit of the
doubt, however, findings should be interpreted with
caution.
Thresholds and reporting of association
Odds ratio, relative risk, c-index and hazard ratio were
used to indicate association of the imaging biomarker
with outcomes. There was selective reporting of sub-
groups and p values among the reported subgroups
(Table 2). The reference groups of investigations were
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not consistent. In CTCA, the reference group could ei-
ther be no disease or non-obstructive disease. In both
TACS and CACS, the reference group was not always a
score of zero. The Additional file 1 displays the details
regarding the thresholds of different types of investiga-
tion. The cut points that define respective categories
were also variable.
Intended population for Framingham risk score
Four studies (11.4%) had an exclusively Caucasian popula-
tion [5, 13, 52, 53]. Eleven studies (31.4%) had more than
10% non-Caucasian population [41, 48–51, 54, 57, 58, 61,
66, 68]. Twenty two studies (62.9%) had not recorded eth-
nicity as a variable [4, 9, 14, 40, 42–47, 52, 53, 55, 56, 58–
60, 62–65, 67]. Five studies (14.3%) had documented CHD
at baseline [45, 57, 63, 65, 67]. Considering all the infor-
mation, only 4 studies (11.4%) were identified as similar to
the original Framingham population [5, 13, 52, 53].
Documentation of regression, discrimination & AUC
analysis
Of the 35 studies, the majority appropriately reported
multivariable regression (74.3%). Thirty three studies re-
ported AUC estimates for both FRS alone and the FRS
with additional CT biomarkers with data on 76 such
pairs of data. Appropriate documentation of AUC was
not common practice (36.4%). The method used to
compare receiver operating characteristics curves was
not always described (39.4%). Only eight studies re-
ported calibration (22.9%) [4, 48, 51–55, 68]. Table 3
shows the reporting of regression and discrimination.
Fig. 1 The Preferred Reporting Items for Systematic Reviews and Meta-analysis Flow Diagram
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The AUC of FRS alone ranged from 0.53 to 0.77 (me-
dian = 0.68). The Δ AUC ranged from − 0.07 to 0.24
(median = 0.06). There was strong inverse correlation be-
tween the Δ AUC and the baseline FRS AUC (Spearman
correlation coefficient, − 0.46, p < 0.0001). When the
baseline FRS AUC performed well, the Δ AUC was rela-
tively lower with the addition of a CT biomarker (Fig. 3).
Table 4 shows the median AUC values and the Δ AUC
when the data was classified according to features of de-
sign and analysis [15]. The baseline FRS AUC performs
better with minor alterations compared with those with
major alterations of the Framingham model (p = 0.0006).
The improvement in AUC was greater in those with
major alterations of the Framingham model (p = 0.015).
Other factors that significantly affected the performance
of AUC included the exploration of data analysis, report-
ing of calibration and validation, multivariable and AUC
documentation (all p < 0.05). The types of incremental
value reported were associated with a difference in AUC
performance, but only significant when a threshold of 2
was chosen. In the sample population, measurement of
CHD as an outcome or whether the population was
similar to the original Framingham cohort did not sig-
nificantly alter the AUC performance.
Documentation of reclassification and NRI analysis
Twenty three studies reported NRI estimates and all had
at least 2 cut-offs, with those that had 3 cut-offs making
up the biggest NRIs [59, 67]. The number of thresholds
influenced the value of NRI [70]. The most commonly
used type of NRI was categorical NRI (69.6%). The
studies that reported calibration were the same as those
documented in the last section. Table 3 shows the
reporting of reclassification analysis and NRI. Complete
reporting of reclassification analysis using reclassification
table or text was not common practice (31.4%). When
reclassification analysis was done, only half was consid-
ered appropriate (56.3%). The actual number of patients
being up or down classified to a different risk group was
not documented. In conjunction with the documentation
of NRI, the proportion of subjects being correctly reclas-
sified was not always available (43.8%). Most studies
subjectively drew strong conclusions from the NRI cal-
culated (68.7%). The individual components of events
and non-events and also their respective NRI compo-
nents were not always available (at least 43.8%). Fifteen
studies reported categorical NRI with 46 data points.
The values of categorical combined NRI ranged from −
0.083 to 0.785 (median = 0.249). None of the aspects of
reporting [37] was significantly related to the difference
in the values of categorical combined NRI (Table 5).
Discussion
The majority of studies claimed improved discrimination
and reclassification of the outlined CT biomarkers over
the established Framingham model. For association, haz-
ard ratios were commonly used but the variation in
reporting practice hindered evidence synthesis. Although
Fig. 2 Bias assessment of included studies using the Quality in Prognosis Studies tool
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all studies used a similar baseline model for AUC analysis,
the performance of FRS varied. There was a clear negative
correlation between improved discrimination and baseline
performance of FRS. In contrast, despite the poor report-
ing, there was no difference in the magnitude of categor-
ical NRI between adequate and inadequate reporting
practice.
Selective reporting of association is known and remains
an issue [16]. We found that non-standardisation of
thresholds and different reference groups across studies
prohibit future meta-analysis. Here we substantiate this
with 3 included studies. Chow et al. used non-obstructive
coronary disease as the reference group for 3 different
composite outcomes [65]. The same author then used no
coronary artery disease as the reference group in the
CONFIRM cohort [63]. In [66], we estimated hazard
ratios using Kaplan-Meier curve [34]. When non-
obstructive coronary disease is the reference group, the es-
timated association of obstructive disease with composite
outcome is smaller (HR = 2.03, 95% CI 1.47–2.79),
compared with when no coronary disease/normal is the
reference, the estimated association is bigger (HR = 3.24,
95% CI 2.28–4.63) [66].
NRI records the transformation in predicted risk that
changes from one category to another category after the
introduction of an additional test. However, it is only
meaningful when the information about risk thresholds
is available. The change in predicted risk could be cor-
rect or incorrect. In this population, the concept that the
subject could be wrongly reclassified with an additional
test was not clearly outlined. The combined NRI could
have been driven by predominantly event NRI, leading
to overestimation. This could have been clarified by
reporting of the components of NRI but this was not
standard practice, despite recommendation [17]. Deriv-
ing from concern about miscalibration, another recom-
mendation was the regular reporting of calibration [26,
71, 72], with graphical plot being the best assessment
[73]. Calibration, however, was regularly overlooked. To
counteract the issues with missing data, we have met so-
lutions such as Weibull extrapolation [5, 44, 47] and ad-
justment of risk cut-offs by the ratio of actual follow up.
These strategies translate to a fact that a significant pro-
portion of the included studies used non-standardised
risk categories but almost all managed to justify. A more
definitive solution would be a move towards decision
curve analysis [74]. Only 1 study provided information
to allow adjustment using Kaplan-Meier estimates [54].
This is on a background of insufficient reporting on the
handling of censoring. This adjustment should receive
more attention, especially when censoring happened early
on during follow-up [75]. There is currently no
Table 1 Alteration of the risk factors used for the calculation of
Framingham Risk Score in 35 eligible studies compared to the
Framingham Risk Score 1998, 2002 and 2008
No. of Studies
(n = 35)
Ordinal
outcomes
Items of Alteration (n = 18) Yes No Unclear
Addition
Item 1. Antihypertensive 16 15 4
Item 2. Weight related measures, e.g. BMI 0 35 0
Item 3. Race/ethnic groups 2 33 0
Item 4. Triglycerides 2 33 0
Item 5. Alcohol 0 35 0
Item 6. Previous cardiovascular disease 1 34 0
Item 7. Others (family history, PVD & stroke) 5 30 0
Deletion
Item 8. Diastolic blood pressure 9 21 5
Item 9. aDiabetes 0 19 0
Item 10. HDL cholesterol 4 28 3
Modification
Blood pressure
Item 11. Systolic blood pressure 3 23 9
Item 12. History of hypertension/self-reported
hypertension
7 23 5
Item 13. Other blood pressure definition modification 3 31 1
Lipid levels
Item 14. History of hyperlipidaemia/ self-reported
hyperlipidaemia
14 14 7
Diabetes
Item 15. aFasting glucose > 126 mg/dL or 7.8 mmol/L 0 19 0
Item 16. aSelf-reported diabetes/ use diabetic
medication
3 10 6
Smoking
Item 17. Pack years of smoking 0 34 1
Item 18. Use of ex-smoker category 11 23 1
Abbreviations: BMI body mass index, HDL high density lipoprotein, PVD
peripheral vascular disease
a13 studies used FRS 2002 and 3 studies used FRS 2008 and diabetes related
items were discounted
Table 2 Selective reporting of association
Reference
groups, n
Subgroups, n Reported
subgroups,
n (%)
Missing
p-value, n (%)
All effect
sizes
92 381 328 (86) 85 (26)
OR 4 27 27 (100) 9(33)
RR 8 37 37 (100) 18 (49)
C-index 0 22 22 (100) 0 (0)
HR 80 295 242 (82) 58 (24)
Abbreviations OR odds ratio, RR relative risk, c-index index of concordance, HR
hazard ratio
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Table 3 Documentation of multivariable regression, calibration, discrimination and reclassification
Part 1. Documentation of multivariable regression (n = 35) No. (%)
a. Information on whether additional predictor is significant at <.05 level 24 68.6
b. Results of a test that penalises for the inclusion of additional predictor 8 22.9
Appropriate documentation (1a or 1b) 26 74.3
Part 2. Documentation of AUC in ROC analysis (n = 33)
a. Described method used to compare ROC curves 13 39.4
b. Presented the AUC values with and without the additional predictor 31 93.9
c. Presented CIs of AUC values with and without additional predictor 9 27.3
d. Presented P value for comparison 26 78.8
f. Availability or enable calculation of Δ AUC CIs 30 90.9
Appropriate documentation 1 (2a and 2b and [2c or 2d]) 11 33.3
Appropriate documentation 2 (2a and 2b and [2c or {2d or 2f}]) 12 36.4
Part 3. Documentation of calibration (n = 35)
Documentation of Hosmer-Lemeshaw test (n = 7) or Schoenfeld residuals (n = 1) 8 22.9
Part 4. Documentation of reclassification analysis (n = 35)
Report using table or text
Not reported 19 54.3
Partial 5 14.3
Complete 11 31.4
Standard of reporting of reclassification analysis (n = 16)
a. Use of standard categories of risk 11 68.8
b. Justified use of other categories of risk 15 93.8
c. Reported the number of patients changing categories 9 56.3
Appropriate documentation ([4a or 4b] and 4c) 9 56.3
Inadequate 7 43.8
Part 5. Documentation of NRI (n = 23)
Type of NRIs
Continuous/ category-free NRI 4 17.4
Categorical NRI 16 69.6
Reported both continuous & categorical NRIs 1 4.3
Reported relative NRI 1 4.3
Unclear 3 13.0
Standard of reporting of categorical NRI (n = 16)
a. Report censor handling 5 31.3
b. No extrapolation 7 43.8
c. Categorical NRI reference available 14 87.5
d. Justification of risk categories 14 87.5
e. Report NRI components 5 31.3
f. Availability of reclassification table showing event and non-event 8 50.0
g. Reclassification table enables the calculation of NRI components 7 43.8
h. Combined NRI reported as a sum not a percentage 8 50.0
i. The proportion of correctly reclassified subjects available 7 43.8
j. Reported NRI not used to construct strong summary 5 31.3
Adequate reporting of categorical NRI (> 5 items listed 5a–j)a 11 68.8
aThe threshold is the median number of items reported in a skewed sample
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consensus on what is a large enough NRI. Overall, con-
sidering the uncertainty in NRI [17] and the small values
of NRI, one should not draw strong conclusions from
the use of NRI alone. Given the popularity of NRI in car-
diovascular research [26], a framework of reporting NRI
should be followed, for example in [37].
Discrimination as measured by AUC analysis is an
established method of measuring incremental value [76].
It was reported in almost all the studies but adequate
documentation was not common practice. In our study,
reporting of calibration, validation and AUC documenta-
tion all influenced the values of AUC. The baseline
Framingham model is an established score even consid-
ering its various iterations [1]. Big improvements in AUC
was seen in cases where the baseline model performed
badly. This echoes previous findings [15] but in a more
defined population. As eluded to in [15], this phenomenon
is similar to when a new drug is only effective when com-
pared to an ineffective comparator drug [77]. In addition
to the above, inadequate reporting practices were associ-
ated with inflated estimates.
Our investigation on AUC [15] and NRI [17] were not
empirical and can only serve as an update in a different
population. The assessment on thresholds was minimal
compared with previous investigation [17]. The harm of
imaging using CT (radiation burden) was not explored.
The focus was solely on the potential benefit. Studies
that indicated association or only had a reclassification
table could be excluded because we focused on studies
that had at least 1 summary estimate that indicated in-
cremental value. We were unable to assess publication
bias where articles showed no or worsening prediction if
these studies remain unpublished. The calculation of
model coefficients can significantly impact the baseline
AUC. There are different ways of calculating the model
coefficients (re-estimation for the new population, using
published coefficients or a point based model) but these
were not explored. The difference between using CHD
or CVD as an outcome was investigated, however, the
justification and transparency of reporting outcomes was
not examined.
Association on its own is insufficient to substantiate
incremental value [78] and large values are infrequent in
biomarker research [79]. AUC analysis is seen as a good
starting point and reclassification should follow rather
than replace AUC analysis [76]. However, AUC analysis
Fig. 3 The correlation between difference in AUC and baseline Framingham Risk Score AUC
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is not without fault [79]. Transparent reporting of NRI
should be compulsory, for example use of a reclassification
table (38), and readers should be aware of the controver-
sies surrounding NRI [80]. The co-existence of a lack of
increase in AUC and a positive NRI should alarm readers
[81]. In general, the reporting in prognosis studies needs
to be more robust [82–85]. Data should be made available
for individual patient data meta-analysis.
Conclusion
Inconsistent thresholds, reference groups and selective
reporting prohibit future evidence synthesis of associations.
Inadequate documentation of discrimination, calibration and
validation are widespread. The variable baseline performance
and other aspects of reporting discrimination inflate poten-
tial incremental values. Reporting of reclassification is also
insufficient but significant differences between adequate and
inadequate reporting practice have not been identified.
Additional file
Additional file 1: Threshold information of coronary and thoracic calcium
scores, and computed tomographic coronary angiogram. (DOCX 18 kb)
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Table 5 Median NRI values according to different aspects of
design and analysis
No. NRI (median) IQR P value
1. Reporting of censor handling
Yes 13 0.18 0.14–0.43
No 33 0.26 0.19–0.35 0.4869
2. No extrapolation
Yes 20 0.28 0.14–0.49
No 26 0.23 0.16–0.34 0.4186
3. Category NRI referencea
Quoted 38 0.25 0.18–0.39
Not quoted 8 0.18 0.00–0.38 0.1922
4. Justification of NRI categoriesa
Yes 40 0.25 0.15–0.41
No 6 0.21 0.18–0.29 0.7691
5. Reporting NRI components
Yes 22 0.24 0.13–0.34
No 24 0.28 0.19–0.48 0.1907
6. Reclassification table showing the number of events and non-events
Yes 32 0.27 0.18–0.37
No 14 0.21 0.14–0.43 0.3396
7. The availability of reclassification table with sufficient information to
enable the calculation of event and non-event NRI
Yes 30 0.25 0.18–0.35
No 16 0.23 0.14–0.48 0.9265
8. Describing the combined NRI as sum not a percentage
Yes 25 0.28 0.14–0.47
No 21 0.22 0.18–0.30 0.256
9. Provide any indication of the proportion of correctly reclassified
Yes 15 0.35 0.14–0.53
No 31 0.23 0.16–0.34 0.0916
10. Strong conclusion based on the reporting of NRI
No 20 0.29 0.19–0.48 No
Yes 26 0.23 0.13–0.34 0.08
11. NRI adequate documented
Adequate 39 0.25 0.14–0.39
Inadequate 7 0.24 0.20–0.49 0.7949
12. Types of incremental value
> 3 18 0.28 0.2–0.44
< 3 28 0.23 0.13–0.37 0.2464
Abbreviations: IQR interquartile range, NRI net reclassification index
P values generated using Wilcoxon ranksum test
aOne group has less then 10 studies and therefore the comparison is limited
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